FDA Approves the first Mesenchymal Stromal Cell Therapy to Treat the Graft Versus Host Disease in Adults and Children

Mesoblast Biotechnology Company has received FDA approval for its Ryoncil therapy as the first of its kind to be approved in the United States. The therapy has been developed to…

Continue Reading FDA Approves the first Mesenchymal Stromal Cell Therapy to Treat the Graft Versus Host Disease in Adults and Children
The FDA Rejects New Drug for SR-aGVHD, Shocking Scientists and Patients
source: pixabay.com

The FDA Rejects New Drug for SR-aGVHD, Shocking Scientists and Patients

As reported in BioSpace, the FDA shocked Mesoblast executives, a stem-cell research company, when this October, they rejected the Biologics License Application (BLA) for the drug Ryoncil, meant to treat…

Continue Reading The FDA Rejects New Drug for SR-aGVHD, Shocking Scientists and Patients